Format

Send to

Choose Destination
Acta Neurol Scand. 2002 Nov;106(5):292-8.

sPECAM-1 in serum and CSF of acute ischaemic stroke patients.

Author information

1
Department of Clinical Neuroimmunology, University School of Medicine, Poznan, Poland. jlosy@mail.usoms.poznan.pl

Abstract

OBJECTIVES:

As platelet endothelial cell adhesion molecule-1 (PECAM-1) is one of key mediators of transendothelial migration of leucocytes during inflammation, and inflammatory reaction is observed in cerebral ischaemia, we decided to determine the levels of soluble PECAM-1 (sPECAM-1) in serum and cerebrospinal fluid (CSF) of patients with acute stroke.

MATERIAL AND METHODS:

Twenty-three patients with first-ever in a lifetime completed ischaemic stroke have been studied. CSF and blood samples were obtained within 24 h of the onset of stroke and the levels of sPECAM-1 in serum and CSF were quantified by ELISA.

RESULTS:

Stroke patients displayed statistically significant higher levels of sPECAM-1 in sera and CSF in comparison with control group. The levels were significantly higher in serum than in CSF, correlated between each other, and CSF sPECAM-1 fraction was blood-derived.

CONCLUSION:

Our results indirectly suggest that PECAM-1 may play a role in the pathophysiological events during early phase of ischaemic stroke.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center